PolyNovo (ASX:PNV) logged a total monthly revenue of AU$12.4 million in March, up nearly 49% compared with the same time in 2024, according to a Wednesday filing with the Australian bourse.
Commercial sales climbed over 71% to AU$11.9 million. This was buoyed by record monthly sales of AU$9.3 million in the US, a 93% increase on the year-ago period.
Sales in the year to March surged 31% to AU$84.4 million.
In the same filing, the company said it has roughly 10 months of inventory on hand in the US and does not expect a material impact from the US tariffs based on preliminary assessment.
The medical device company's shares were down 8% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。